XFOR•benzinga•
X4 Pharmaceuticals Announced That They Have Entered Into An Exclusive Agreement For The Distribution And Commercialization Of Xolremdi (Mavorixafor), An Oral, Once-daily Treatment For Whim Syndrome, In Select Middle East Countries, Following Any Approvals
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 19, 2025 by benzinga